echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > LINEPHARMA submits abortion drug license application in Japan

    LINEPHARMA submits abortion drug license application in Japan

    • Last Update: 2022-03-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 23, Linepharma International Ltd.


    If successfully submitted in Japan, the drug would be the first approved abortion drug in Japan


    The world's first combined mifepristone and misoprostate drug combination will be released in Japan under the name MEFEEGO™


    Approximately 73 million abortions are performed worldwide each year


    references

    i JOGC 2019 Barriers and Facilitators to the Implementation of first Trimester Medical Abortion with Mifepristone in the Province of Québec: A Qualitative Investigation Marie- Soleil Wagner, MD, MS; Sarah Munro, PhD; Elizabeth S.


    iiBearak J, Popinchalk A, Ganatra B, Moller AB, Tunçalp Ö, Beavin C,


    v

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.